Back to top
more

Guardant Health (GH)

(Real Time Quote from BATS)

$29.44 USD

29.44
1,137,426

-0.77 (-2.55%)

Updated Nov 15, 2024 01:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Has Guardant Health (GH) Outpaced Other Medical Stocks This Year?

Is (GH) Outperforming Other Medical Stocks This Year?

Is Guardant Health (GH) Outperforming Other Medical Stocks This Year?

Is (GH) Outperforming Other Medical Stocks This Year?

Exact Sciences Gets FDA Nod for Label Expansion of Cologuard

Exact Sciences (EXAS) gets FDA approval for use of its noninvasive colorectal cancer screening test, Cologuard, in eligible average-risk individuals aged 45 years or older.

The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health

The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health

Tirthankar Chakraborty headshot

3 Cancer Treatment Stocks to Enrich Your Portfolio

Investments in cancer therapies are expected to rise almost $250 billion by 2023, from $150 billion in 2018. Thus, companies that are coming up with innovative methods to cure this malaise are great investment choices.

AMAG Q2 Loss Widens, Sales Lag Estimates, 2019 Guidance Cut

AMAG Pharmaceuticals (AMAG) reports wider-than-expected loss and sales miss in the second quarter of 2019. The company lowers its 2019 view.

Arena Pharmaceuticals' (ARNA) Q2 Loss Widens, Revenues Meet

Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the second quarter of 2019 while revenues are in line.

Has Guardant Health (GH) Outpaced Other Medical Stocks This Year?

Is (GH) Outperforming Other Medical Stocks This Year?

Top Ranked Momentum Stocks to Buy for August 5th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 5th

Guardant Health (GH) to Report Q2 Earnings: What's in Store?

Guardant Health (GH) will provide updates on Guardant360 and GuardantOMNI tests during the second-quarter 2019 earnings call.

The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health

The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health

Kevin Cook headshot

46 and You: Genetic Testing = Giant Growth Market

Advances in genomic diagnostic technology have made testing affordable for the 99.0% of the world still in line.

The Zacks Analyst Blog Highlights: Guardant, Illumina, Exact Sciences and Pfizer

The Zacks Analyst Blog Highlights: Guardant, Illumina, Exact Sciences and Pfizer

Guardant Health (GH) Looks Good: Stock Adds 6% in Session

Guardant Health (GH) saw a big move last session, as its shares jumped 6% on the day, amid huge volumes.

Tirthankar Chakraborty headshot

3 Stocks to Win Big in the Fight Against Cancer

We highlight three stocks that are using innovative ways to treat cancer, also called malignancy. These stocks are also great long-term investments.

Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More

Five drug/biotech stocks are scheduled to release their first-quarter results on May 9. Let's take a look at how these companies are poised ahead of their earnings release.

Guardant Health (GH) to Report Q1 Earnings: What's in Store?

At Guardant Health's (GH) Q1 conference, investors will watch out for the updates on liquid biopsy-based Guardant360 and GuardantOMNI tests that could help detect advanced stages of cancer.

Guardant Health (GH) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Guardant Health (GH) closed at $66.12, marking a -1.9% move from the previous day.